Phlow key facts
as of Oct 2026- Operator of a pharmaceutical company intended to provide low-cost pharmaceuticals and reduce dependency on foreign supply chains.
- Phlow is valued at approximately $441.4M as of Oct 2026 (last reported valuation).
- It has raised $91.5M; the latest was Later Stage VC ($30.5M) in Feb 2025.
- Notable investors include Virginia Innovation Partnership Corporation, Virginia Venture Partners, Align Private Capital, Bagel Boy Equity Group, Whole Orange Equity.
- Status: Privately Held (backing).
Phlow's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·Watch Phlow: the Monday email on marks, rounds and moves
Phlow funding rounds
No funding rounds for Phlow are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Phlow valuation
Phlow's last reported valuation was $441 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Phlow investors
5 investors are on record for Phlow, including Virginia Innovation Partnership Corporation, Virginia Venture Partners, Align Private Capital and Bagel Boy Equity Group.
About Phlow
Operator of a pharmaceutical company intended to provide low-cost pharmaceuticals and reduce dependency on foreign supply chains. The company's products include precursor chemical ingredients, active healthcare ingredients, and finished pharma products, domestically for essential medicines and to ensure quality, safety, and affordability, enabling practitioners to provide essential medicines to their patients.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Founded
- 2020
- Employees
- 113
- Website
- phlow-usa.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.